HAE Stock: Price, Earnings History and SEC Filings
Haemonetics Corporation (HAE) last traded at $119.65, down 0.12% on the latest session and up 13.6% over the past month. In its most recent reported quarter (Jun 2026) earnings per share were $1.14 against an analyst estimate of $1.07, a beat of 6.5%.
$119.65 -0.12%
1 month+13.63%
52-week high$123.77
52-week low$49.24
Volume452,863
ExchangeNYSE
Price data from Yahoo Finance, as of Oct 30, 2026. May be delayed.
HAE earnings history
| Quarter | Reported | EPS | Estimate | Surprise |
|---|---|---|---|---|
| Jun 2026 | Aug 6, 2026 | $1.14 | $1.07 | +6.54% |
| Mar 2026 | May 7, 2026 | $1.29 | $1.28 | +0.78% |
| Dec 2025 | Feb 5, 2026 | $1.31 | $1.27 | +3.15% |
| Sep 2025 | Nov 6, 2025 | $1.27 | $1.12 | +13.39% |
HAE beat the analyst EPS estimate in 4 of its last 4 reported quarters. Source: Nasdaq.
Latest SEC filings for HAE
SEC filing data is not available right now. You can search for HAE on SEC EDGAR.
HAE news
- GEHC vs. HAE: Which Stock Is the Better Value Option?Oct 29, 2026 · finance.yahoo.com
- Blood Plasma Name Hits Highs On FDA Approval As Earnings LoomOct 28, 2026 · finance.yahoo.com
- Haemonetics Corporation (HAE) Gains on Strong Plasma Growth and Higher Guidance, Ariel Appreciation Fund SaysOct 28, 2026 · finance.yahoo.com
- All You Need to Know About Haemonetics (HAE) Rating Upgrade to BuyOct 27, 2026 · finance.yahoo.com
- Haemonetics (HAE): Buy, Sell, or Hold Post Q2 Earnings?Oct 21, 2026 · finance.yahoo.com
- Nasdaq Jumps Past 1 Percent as VIX Swings While Dow Dips Below Its 50-Day LineOct 19, 2026 · finance.yahoo.com
- Haemonetics Announces FDA Approval of PerQseal® Elite Vascular Closure SystemOct 19, 2026 · finance.yahoo.com
About Haemonetics Corporation
Haemonetics Corporation (HAE) is a US-listed public company on NYSE.